171 related articles for article (PubMed ID: 37700010)
21. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.
Henk HJ; Teitelbaum A; Perez JR; Kaura S
Am J Hematol; 2012 May; 87(5):490-5. PubMed ID: 22454220
[TBL] [Abstract][Full Text] [Related]
22. Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis.
Lesclous P; Cloitre A; Catros S; Devoize L; Louvet B; Châtel C; Foissac F; Roux C
Bone; 2020 Aug; 137():115412. PubMed ID: 32404281
[TBL] [Abstract][Full Text] [Related]
23. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
24. A Strategy against the Osteonecrosis of the Jaw Associated with Nitrogen-Containing Bisphosphonates (N-BPs): Attempts to Replace N-BPs with the Non-N-BP Etidronate.
Oizumi T; Yamaguchi K; Sato K; Takahashi M; Yoshimura G; Otsuru H; Tsuchiya M; Hagiwara Y; Itoi E; Sugawara S; Takahashi T; Endo Y
Biol Pharm Bull; 2016; 39(9):1549-54. PubMed ID: 27582334
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
[TBL] [Abstract][Full Text] [Related]
26. The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes.
Degli Esposti L; Perrone V; Sangiorgi D; Andretta M; Bartolini F; Cavaliere A; Ciaccia A; Dell'orco S; Grego S; Salzano S; Ubertazzo L; Vercellone A; Gatti D; Fassio A; Viapiana O; Rossini M; Adami G
J Bone Miner Res; 2021 Nov; 36(11):2177-2183. PubMed ID: 34405441
[TBL] [Abstract][Full Text] [Related]
27. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
29. Effect of Bisphosphonates on Fracture Outcomes Among Frail Older Adults.
Zullo AR; Zhang T; Lee Y; McConeghy KW; Daiello LA; Kiel DP; Mor V; Berry SD
J Am Geriatr Soc; 2019 Apr; 67(4):768-776. PubMed ID: 30575958
[TBL] [Abstract][Full Text] [Related]
30. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
Nasomyont N; Hornung LN; Gordon CM; Wasserman H
Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029
[TBL] [Abstract][Full Text] [Related]
31. Role of zoledronic acid in the prevention and treatment of osteoporosis.
Räkel A; Boucher A; Ste-Marie LG
Clin Interv Aging; 2011; 6():89-99. PubMed ID: 21594000
[TBL] [Abstract][Full Text] [Related]
32. The role of zoledronic acid in the management of osteoporosis.
Maricic M
Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
[TBL] [Abstract][Full Text] [Related]
33. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
34. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Jeffery TC; Chang AB; Conwell LS
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD002010. PubMed ID: 36625789
[TBL] [Abstract][Full Text] [Related]
36. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
[TBL] [Abstract][Full Text] [Related]
37. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonate Use After Hip Fracture in Older Adults: A Nationwide Retrospective Cohort Study.
Nordström P; Toots A; Gustafson Y; Thorngren KG; Hommel A; Nordström A
J Am Med Dir Assoc; 2017 Jun; 18(6):515-521. PubMed ID: 28238673
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
40. Once-yearly zoledronic acid in hip fracture prevention.
Demontiero O; Duque G
Clin Interv Aging; 2009; 4():153-64. PubMed ID: 19503777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
